Enveric Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Enveric Biosciences, Inc. carries a market capitalization of 1.18M, placing it among publicly traded companies globally. Its enterprise value stands at -2.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.18M |
| Enterprise Value | -2.05M |
Share Statistics
Enveric Biosciences, Inc. currently has 1.89M shares outstanding.
| Shares Outstanding | 1.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | -0.36 |
| P/OCF Ratio | -0.36 |
Financial Position
Enveric Biosciences, Inc. maintains a current ratio of 11.67, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.67 |
| Quick Ratio | 10.66 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -154.76 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Enveric Biosciences, Inc.'s stock has declined approximately -87.2093% over the past 52 weeks. The 50-day moving average sits at 2.67, while the 200-day moving average is 5.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | -87.2093% |
| 50-Day Moving Average | 2.67 |
| 200-Day Moving Average | 5.33 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.06M, while operating income came in at -8.22M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.22M |
| Pretax Income | -8.22M |
| Net Income | -8.22M |
| EBITDA | -8.06M |
| EBIT | -8.22M |
| Earnings Per Share (EPS) | -5.58 |
Balance Sheet
Total book value stands at -116.46M, with working capital of 4.91M providing operational flexibility.
| Cash & Cash Equivalents | 4.91M |
| Total Debt | N/A |
| Net Debt | -4.91M |
| Equity (Book Value) | -116.46M |
| Book Value Per Share | -79.06 |
| Working Capital | 4.91M |
Cash Flow
Enveric Biosciences, Inc. produced -8.01M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.01M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.01M |
| FCF Per Share | -5.44 |
Dividends & Yields
The company's payout ratio of 15.55 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | 15.55 |
| Shareholder Yield | -302.11 |
| FCF Yield | -280.17 |
Stock Splits
Enveric Biosciences, Inc.'s most recent stock split took place on October 28, 2025 with a 12:1 split ratio.
| Last Split Date | 10/28/2025 |
| Split Ratio | 12:1 |
Scores
Enveric Biosciences, Inc. posts an Altman Z-Score of -29.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.66 |